

Date: 10<sup>th</sup> November, 2022

To,  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 511523

**Sub.: Unaudited Financial Results for the quarter and half year ended September 30, 2022**

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statement showing the Unaudited Financial Results for the quarter and half year ended September 30, 2022.
2. Limited Review Report on the Unaudited Financial Results for the quarter and half year ended September 30, 2022.

Thanking You.

Yours faithfully,  
For **Veerhealth Care Limited**

Bhavin S. Shah  
Managing Director  
DIN: 03129574



Encl: As above

Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2022

(Rs. in lakhs)

Sr. No.	Particulars	Standalone					
		Quarter ended 30-09-2022	Quarter ended 30-06-2022	Quarter ended 30-09-2021	Half year ended 30-09-2022	Half year ended 30-09-2021	Year ended 31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	392.84	285.63	247.44	678.47	496.19	962.61
II	Other Income	41.53	4.96	36.77	46.57	60.06	166.74
III	<b>Total Revenue (I + II)</b>	<b>434.37</b>	<b>290.59</b>	<b>284.21</b>	<b>725.04</b>	<b>556.25</b>	<b>1129.35</b>
IV	Expenses:						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	216.21	233.89	144.10	450.10	365.12	738.33
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	66.55	-53.49	39.39	13.06	-9.64	-46.10
	(d) Employee benefits expense	20.31	21.81	17.41	42.12	34.29	87.75
	(e) Finance Costs	0.00	0.02	1.25	0.02	4.60	8.51
	(f) Depreciation and amortisation expense	15.43	14.74	13.13	30.17	25.73	52.42
	(g) Other expenses	96.84	62.86	65.37	159.78	126.73	264.68
	<b>Total Expenses</b>	<b>415.34</b>	<b>279.83</b>	<b>280.65</b>	<b>695.25</b>	<b>546.83</b>	<b>1105.59</b>
V	<b>Profit/(Loss) before exceptional items (III - IV)</b>	<b>19.03</b>	<b>10.76</b>	<b>3.56</b>	<b>29.79</b>	<b>9.42</b>	<b>23.76</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before tax (V - VI)</b>	<b>19.03</b>	<b>10.76</b>	<b>3.56</b>	<b>29.79</b>	<b>9.42</b>	<b>23.76</b>
VIII	Tax expense:						
	1) Current Tax	5.00	1.50	0.52	6.50	1.40	3.75
	2) Prior Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Deferred Tax	0.29	0.00	0.00	0.29	0.00	29.65
IX	<b>Profit/(Loss) for the period (VII - VIII)</b>	<b>13.74</b>	<b>9.26</b>	<b>3.04</b>	<b>23.00</b>	<b>8.02</b>	<b>-9.64</b>
X	Other Comprehensive Income						
	(a) Items that will not be reclassified to Profit or Loss	-0.86	-0.86	-2.43	-1.72	-4.86	8.07
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Other Comprehensive Income</b>	<b>-0.86</b>	<b>-0.86</b>	<b>-2.43</b>	<b>-1.72</b>	<b>-4.86</b>	<b>8.07</b>
XI	<b>Total Comprehensive Income for the period (IX + X)</b>	<b>12.88</b>	<b>8.40</b>	<b>0.61</b>	<b>21.28</b>	<b>3.16</b>	<b>-1.57</b>
XII	Paid-up equity share capital of Rs. 10 each	693.42	693.42	693.42	693.42	693.42	693.42
XIII	Other Equity				724.46	714.06	701.64
XIV	Net Worth				1417.88	1407.48	1395.06
XV	Earnings Per Share (of Rs. 10 each):						
	(a) Basic (in Rs.)	0.19	0.12	0.04	0.31	0.12	-0.14
	(b) Diluted (in Rs.)	0.19	0.12	0.04	0.31	0.12	-0.14

*T. Vasudevan*



VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th November, 2022. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors. The limited review report does not contain any observation which would have an impact on the above results.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ('SEBI').
- 3 During the quarter ended September 30, 2022 the Company is operating in a single segment i.e. "Ayurved Pharma Products". Accordingly, segment wise reporting is not applicable.
- 4 Figures of the previous periods have been rearranged / regrouped, wherever necessary.
- 5 The financial results of the Company are available at [www.bseindia.com](http://www.bseindia.com) and at [www.veerhealthcare.net](http://www.veerhealthcare.net).

Place: Mumbai  
Date: 10th November, 2022



By order of the Board  
For Veerhealth Care Limited

A handwritten signature in black ink, appearing to read 'Bhavin S. Shah'.

Bhavin S. Shah  
Managing Director  
DIN: 03129574



Statement of Assets and Liabilities

(Rs. in lakhs)

	Particulars	As at	As at
		30-09-2022	31-03-2022
		Unaudited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property Plant & Equipment	1062.91	1054.03
	(b) Capital work in progress	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Intangible assets under development	0.00	0.00
	(e) Financial Assets		
	(i) Investments	0.00	0.00
	(ii) Trade receivables	1.03	0.00
	(iii) Loans	0.00	0.00
	(iv) Others	211.58	249.23
	(f) Deferred Tax Asset (Net)	0.00	0.00
	(g) Other Non-Current Assets	81.90	88.96
	<b>Total Non-Current Assets</b>	<b>1357.42</b>	<b>1392.22</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	199.34	212.40
	(b) Financial Assets		
	(i) Investments	0.00	0.00
	(ii) Trade receivables	228.12	154.09
	(iii) Cash & cash equivalents	46.07	40.39
	(iv) Bank Balances other than (iii) above	0.00	0.00
	(v) Loans	147.26	150.50
	(vi) Others	0.00	0.00
	(c) Current Tax Assets (Net)	0.00	0.00
	(d) Other Current Assets	24.03	65.47
	<b>Total Current Assets</b>	<b>644.82</b>	<b>622.85</b>
	<b>TOTAL ASSETS</b>	<b>2002.24</b>	<b>2015.07</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity Share Capital	693.42	693.42
	(b) Other Equity	724.46	701.64
	<b>Total Equity</b>	<b>1417.88</b>	<b>1395.06</b>
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	0.00	0.00
	(ii) Trade Payables	0.00	1.37
	(iii) Others	0.00	0.00
	(b) Provisions	19.54	15.79
	(c) Deferred Tax Liabilities (net)	81.21	80.73
	(d) Other Non-Current Liabilities	324.36	275.83
	<b>Total Non-Current Liabilities</b>	<b>425.11</b>	<b>373.72</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	0.00	0.00
	(ii) Trade Payables	145.73	231.86
	(iii) Other Financial Liabilities	0.00	0.00
	(b) Other Current Liabilities	7.02	10.68
	(c) Provisions	6.50	3.75
	<b>Total Current Liabilities</b>	<b>159.25</b>	<b>246.29</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2002.24</b>	<b>2015.07</b>

By order of the Board  
For Veerhealth Care Limited



*[Handwritten Signature]*

Bhavin S. Shah  
Managing Director  
DIN: 03129574

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 Fax. No. 022-22072644 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Cash Flow Statement for six months ended September 30, 2022

(Amount in lakhs)

Particulars	Six months ended September 30, 2022	Six months ended September 30, 2021
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit Before Tax	29.79	9.42
Adjustments for:		
Depreciation	30.17	25.73
Interest and finance charges	0.02	4.60
Interest income	(8.37)	(7.56)
<b>Operating profit before working capital changes</b>	<b>51.61</b>	<b>32.19</b>
Adjustments for changes in working capital:		
(Increase)/decrease in other non current financial assets	37.65	(23.50)
(Increase)/decrease in other non current assets	7.06	(5.14)
Increase in inventories	13.06	(9.64)
(Increase)/decrease in trade receivables, current	(74.03)	8.33
(Increase)/decrease in trade receivables, non-current	(1.03)	0.00
(Increase)/decrease in Balances other than (ii)	0.00	0.00
(Increase)/decrease in loans	3.24	47.41
(Increase)/decrease in other current financial assets	0.00	0.00
(Increase)/decrease in current tax assets	0.00	0.00
(Increase)/decrease in other current assets	41.45	28.03
Increase/(decrease) in provisions, current	2.75	(27.15)
Increase/(decrease) in provisions, non-current	3.75	28.55
Increase /(decrease) in trade payables, current	(86.13)	(5.82)
Increase /(decrease) in trade payables, non-current	(1.37)	0.00
Increase /(decrease) in other non current liabilities	48.53	165.00
Increase /(decrease) in other current liabilities	(3.66)	0.91
<b>Cash generated from/(used in) operations</b>	<b>42.88</b>	<b>239.17</b>
Income taxes paid (net of refund)	(6.50)	(6.25)
<b>Net cash flow from /(used in) operating activities</b>	<b>36.38</b>	<b>232.92</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
Payment for purchase of property, plant and equipment	(39.05)	(50.11)
Interest received	8.37	7.56
<b>Net cash flow from/(used in) investing activities</b>	<b>(30.68)</b>	<b>(42.55)</b>
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
Payment of long term borrowings	0.00	(141.16)
Proceeds/(repayment) from short term borrowings (net)	0.00	(32.02)
Additions in share capital	0.00	0.00
Net increase in other equity	0.00	0.00
Interest and finance charges paid	(0.02)	(4.60)
<b>Net cash flow from financing activities</b>	<b>(0.02)</b>	<b>(177.78)</b>
<b>Net change in cash and cash equivalents (A+B+C)</b>	<b>5.68</b>	<b>12.59</b>
Cash and bank balances at the beginning of the year	40.39	10.18
Cash and bank balances at the end of the year	46.07	22.77

*Travis*





**Limited Review Report**

**To the Board of Directors of Veerhealth Care Limited**

I have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September, 2022, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

I conducted my review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an Audit. I have not performed an audit and accordingly I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of Audited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Jayesh R Shah & Co.**  
**Chartered Accountants**  
**Firm Regn. No.104182W**



**Jayesh Shah**  
**Proprietor**  
**Membership No.033864**



**Place: Mumbai**  
**Date: 10<sup>th</sup> November, 2022**  
**UDIN: 22033864BCSIIE3978**